Compounds > ketoconazole

ketoconazole and erlotinib hydrochloride

ketoconazole has been researched along with erlotinib hydrochloride in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Charoin, JE; Fettner, S; Hamilton, M; Jones, HM; Lum, BL; Pantze, MP; Rakhit, A; Riek, M1
Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R1
Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T1
Chan, ECY; Cheong, EJY; Chin, SY; Ng, DZW; Wang, Z1
Banpurkar, AR; Perdih, F; Wazalwar, SS1

Trials

1 trial(s) available for ketoconazole and erlotinib hydrochloride

ArticleYear
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
    European journal of clinical pharmacology, 2008, Volume: 64, Issue:1

    Topics: Adolescent; Adult; Aged; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Erlotinib Hydrochloride; Forecasting; Humans; Ketoconazole; Male; Microsomes, Liver; Middle Aged; Protein Kinase Inhibitors; Quinazolines

2008

Other Studies

4 other study(ies) available for ketoconazole and erlotinib hydrochloride

ArticleYear
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:10

    Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir

2013
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4

    Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir

2015
Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:5

    Topics: Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Humans; Ketoconazole; Models, Biological; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Rivaroxaban; Venous Thromboembolism

2022
Synthesis, crystal structure and molecular docking study of novel isoxazole derivatives as CYP450 inhibitors in search of anticancer agents.
    Journal of biomolecular structure & dynamics, 2023, Volume: 41, Issue:19

    Topics: Antineoplastic Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Isoxazoles; Ketoconazole; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship

2023